Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC

被引：2
|
作者：
Jin, Y. [1 ,4 ]
Han, Y. [2 ]
Zhang, L. [3 ]
Jin, Y. [1 ,4 ]
Sun, H. [5 ]
机构：
[1] UESTC, Dept Gastrointestinal Surg, Affiliated Canc Hosp, Sch Med,Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
[2] Southwest Med Univ, Dept Med Oncol, Affiliated Hosp, Luzhou, Peoples R China
[3] Chongqing Univ, Dept Med Oncol, Three Gorges Hosp, Chongqing, Peoples R China
[4] UESTC, Dept Med Oncol, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
[5] Chongqing Univ, Dept Gastrointestinal Surg, Canc Hosp, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402P
引用
收藏
页码：S720 / S721
页数：2
相关论文
共 50 条
  • [21] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 653 - 653
  • [22] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001)
    Liu, Jing
    Wu, Junwei
    Zhu, Liangjun
    Yan, Jun
    Mao, Yong
    Tang, Xinyu
    Zhu, Lingjun
    Jiang, Hong
    Wei, Xiaowei
    Shangguan, Chengfang
    Xi, Wenqi
    Shi, Yan
    Shi, Min
    Zhou, Chenfei
    Yang, Hui
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
    Wu, J.
    Zhu, L.
    Zhou, C.
    Shi, M.
    Chen, J.
    Zhao, L.
    Han, Z.
    Wang, C.
    Jiang, J.
    Yan, J.
    Wei, X.
    Mao, Y.
    Yang, X.
    Qin, Z.
    Tang, X.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1510 - S1511
  • [24] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [25] Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
    Xu, M.
    Pu, Y.
    Jiang, Y.
    Liu, H.
    Feng, Y.
    Qian, C.
    Dai, N.
    Li, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S866
  • [26] Efficacy and safety analysis of EP / EC regimen combined with first-line anlotinib hydrochloride in the treatment of extensive small cell lung cancer: Results from a phase II single-arm trial
    Kong, T.
    Chen, L.
    Duan, F.
    Wang, L.
    Zhao, X.
    Hou, X.
    Zhou, H.
    Miao, W.
    Wang, L.
    Hu, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1040 - S1040
  • [27] Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
    Wu, Jun-Wei
    Zhou, Chen-Fei
    Han, Zheng-Xiang
    Zhang, Huan
    Yan, Jun
    Chen, Jun
    Wang, Chun-Bin
    Qin, Zhi-Quan
    Mao, Yong
    Tang, Xin-Yu
    Zhu, Liang-Jun
    Wei, Xiao-Wei
    Cui, Dong-Hai
    Yang, Xiu-Li
    Shi, Min
    Zhao, Li-Qin
    Jiang, Jin-Ling
    Zhu, Wei-You
    Wang, Hong-Mei
    Wang, Chun
    Zhu, Ling-Jun
    Zhang, Jun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [28] Efficacy and safety of anlotinib plus toripalimab as first-line regimen in advanced gastric cancer patients with performance status 2 (PS 2): An open-label, single arm, phase II trial
    Liu, K.
    Qin, B.
    Chen, S.
    Zhong, X.
    Duan, X.
    Wu, Y.
    Ling, Y.
    Sun, L.
    Shi, D.
    Jiao, X.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1469 - S1469
  • [29] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [30] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
12345